Case Study: Preserving Vision in Geographic Atrophy with Complement Inhibitor Therapy

Overview

Complement inhibitor therapy offers a proactive treatment approach for geographic atrophy (GA), slowing lesion progression and preserving vision. In a 70-year-old monocular patient with progressive GA, treatment with an FDA-approved complement inhibitor demonstrated potential to delay vision loss in the better-functioning eye.

Background

Geographic atrophy is a late-stage manifestation of age-related macular degeneration characterized by progressive retinal atrophy leading to vision loss. Historically, management was limited to monitoring and lifestyle modifications due to lack of effective treatments. Complement inhibitor therapy has recently emerged as an FDA-approved option that slows GA progression by approximately 20% to 30% over 2 to 3 years. This therapy is administered via intravitreal injections monthly or every other month, with the latter preferred to reduce side effects and treatment burden.

Data Highlights

Clinical trial data from phase 3 studies (OAKS, DERBY) and long-term data from GALE indicate that complement inhibitor therapy slows GA lesion growth by 20% to 30% over 2 to 3 years. The therapy's safety profile improves with every-other-month dosing compared to monthly administration, reducing risks such as intraocular inflammation and conversion to wet AMD.

Key Findings

• Complement inhibitor therapy transforms GA management from passive monitoring to active treatment.
• The patient’s right eye showed progressive GA lesion growth with hyperfluorescent edges, indicating active disease.
• Initial treatment in the poorer left eye confirmed safety before treating the better-functioning right eye.
• Every-other-month dosing is preferred to balance efficacy and minimize side effects.
• Therapy slows GA progression but does not restore lost vision, aiming to preserve central vision and quality of life.
• Large phase 3 trials support the clinical benefit of complement inhibitors in slowing GA progression.

Clinical Implications

Clinicians should consider complement inhibitor therapy for patients with GA, especially those reliant on a single better-functioning eye, to slow disease progression and preserve vision. Flexible dosing regimens allow tailoring treatment to minimize risks while maintaining efficacy. Early intervention before foveal involvement may help maintain patient independence and quality of life.

Conclusion

Complement inhibitor therapy represents a significant advancement in GA management by slowing lesion growth and preserving vision. This case exemplifies the shift toward proactive treatment strategies that can meaningfully impact patient outcomes.

References

1. OAKS and DERBY Phase 3 Trials; GALE Long-term Data